Marino Stram & Associates LLC Has $1.13 Million Position in Pfizer Inc. (NYSE:PFE)

Marino Stram & Associates LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 5.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 44,585 shares of the biopharmaceutical company’s stock after selling 2,588 shares during the quarter. Marino Stram & Associates LLC’s holdings in Pfizer were worth $1,130,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Kingswood Wealth Advisors LLC raised its position in shares of Pfizer by 271.2% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 236,683 shares of the biopharmaceutical company’s stock valued at $5,842,000 after acquiring an additional 172,913 shares during the period. Cornerstone Wealth Management LLC increased its stake in Pfizer by 8.0% in the first quarter. Cornerstone Wealth Management LLC now owns 88,983 shares of the biopharmaceutical company’s stock valued at $2,255,000 after purchasing an additional 6,592 shares in the last quarter. Shepherd Financial Partners LLC boosted its position in shares of Pfizer by 3.8% during the first quarter. Shepherd Financial Partners LLC now owns 16,964 shares of the biopharmaceutical company’s stock worth $430,000 after purchasing an additional 617 shares in the last quarter. CENTRAL TRUST Co grew its holdings in shares of Pfizer by 9.1% in the 1st quarter. CENTRAL TRUST Co now owns 431,494 shares of the biopharmaceutical company’s stock valued at $10,934,000 after buying an additional 36,044 shares during the period. Finally, Five Oceans Advisors acquired a new position in shares of Pfizer in the 1st quarter valued at $225,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on PFE shares. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price for the company. UBS Group lifted their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Stock Performance

Shares of PFE opened at $24.00 on Wednesday. The stock has a market capitalization of $136.47 billion, a price-to-earnings ratio of 17.39, a PEG ratio of 0.89 and a beta of 0.57. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The firm has a fifty day simple moving average of $23.14 and a 200 day simple moving average of $24.93. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company’s quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.82 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.17%. Pfizer’s dividend payout ratio is 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.